Treatment with dalfampridine (AMPYRA) resulted in clinically relevant improvements in walking speed and endurance in MS patients with limited ambulation and helped improve their motor function

RESULTS: Treatment with dalfampridine resulted in significant improvement in walking speed and endurance (p < 0.05). Walking speed increased by 33% and walking endurance by 31 %, representing clinically meaningful improvement. This change was
not influenced by change in muscle tone. This improvement in mobility was associated with a clinically significant change in motor function.
Adverse effects, including insomnia, dizziness, and headache, were experienced by five patients who discontinued the medication after a minimum of 4 weeks.CONCLUSION: Treatment with dalfampridine resulted in clinically relevant improvements in walking speed and endurance in MS patients with limited ambulation and helped improve their motor function
 OBJECTIVE: The aim of this study was to determine the efficacy of sustained-release fampridine (4-aminopyridine) in veterans with multiple sclerosis (MS) with limited ambulatory ability, and its impact on motor function in an outpatient setting.
MAIN OUTCOME MEASURES:  The primary outcome measures were mean changes in walking speed (10M walk test), walking distance (2MWT), and Total Functional Independence Measure (TFIM). Improvement of >20 % in walking speed was indicated as a clinically meaningful change.